MedTrace Logo

Creation and Validation of a Questionnaire Evaluating Diastasis Recti

NCT04158180 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 125

Last updated 2026-05-22

No results posted yet for this study

Summary

Introduction. Distasis rectus abdominis (DRA) is defined as the presence of divergence between the rectus abdominis muscles along the linea alba. Some authors describe a prevalence of 40% in women up to one year postpartum. Some studies suggest that the presence of DRA can be related to the appearance of low back, pelvic and abdominal pain and even urinary incontinence. These factors can significantly affect the quality of life of women with diastasis both socially, sexual and personal level. According to several studies, this pathology is related to higher rates of depression and an alteration in the self-perception of body image that makes these women to look to specialized medical care.

At present, the quantitative evaluation of DRA is performed purely anatomically. This evaluation consists in measuring the separation between the two rectus abdominis. Currently there is no consensus as to the protocol that should be used for this measurement.

So far, no instrument is able to quantitatively measure the consequences of DRA. The evaluation of symptoms and consequences should include relevant parameters such as quality of life, perception of body image and functional limitations.

The objective of this study is the creation and validation of a specific questionnaire to evaluate the symptoms and consequences of DRA.

Material and methods. A) Development of the questionnaire

1. Literature review
2. Online survey
3. Expert panel
4. Pilot test of the questionnaire

B) Validation of the questionnaire. The psychometric properties of the questionnaire will be evaluated in a sample of patients with DRA. The sample will be composed of a group of adult women with DRA who attended to a physiotherapy clinic.

Conditions

  • Diastasis Recti and Weakness of the Linea Alba
  • Diastasis Recti

Interventions

DIAGNOSTIC_TEST

Questionnaire

A battery of questionnaires will be propose to the participants

Sponsors & Collaborators

  • University Hospital, Caen

    collaborator OTHER

  • University of Valencia

    lead OTHER

Principal Investigators

  • Montserrat Rejano Campo, PhD(c)

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-27
Primary Completion
2026-09-28
Completion
2026-11-15

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04158180 on ClinicalTrials.gov